➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: April 14, 2021

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Levofloxacin, and when can generic versions of Levofloxacin launch?

Levofloxacin is a drug marketed by Akorn, Aurobindo Pharma Ltd, Baxter Hlthcare Corp, Emcure Pharms Ltd, Gland Pharma Ltd, Hospira Inc, Mylan Asi, Zydus Pharms, Micro Labs Ltd India, Mylan Labs Ltd, Rising, Rubicon, Watson Labs Teva, Lannett Co Inc, Apotex Inc, Celltrion, Cipla Ltd, Dr Reddys Labs Inc, Glenmark Generics, Hec Pharm, Hetero Labs Ltd V, Jubilant Generics, Lupin, Macleods Pharms Ltd, Mylan, Orchid Hlthcare, Sandoz, Teva, Torrent Pharms, Watson Labs Inc, Zydus Pharms Usa Inc, Fresenius Kabi Usa, Hikma Farmaceutica, and Inforlife. and is included in forty-two NDAs.

The generic ingredient in LEVOFLOXACIN is levofloxacin. There are thirty-one drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Levofloxacin

A generic version of LEVOFLOXACIN was approved as levofloxacin by AKORN on December 20th, 2010.

  Start Trial

Drug patent expirations by year for LEVOFLOXACIN
Drug Prices for LEVOFLOXACIN

See drug prices for LEVOFLOXACIN

Drug Sales Revenue Trends for LEVOFLOXACIN

See drug sales revenues for LEVOFLOXACIN

Recent Clinical Trials for LEVOFLOXACIN

Identify potential brand extensions & 505(b)(2) entrants

Shaheed Benazir Bhutto University Sheringal Dir UpperPhase 1
PolyActiva Pty LtdPhase 1
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityN/A

See all LEVOFLOXACIN clinical trials

Paragraph IV (Patent) Challenges for LEVOFLOXACIN
Tradename Dosage Ingredient NDA Submissiondate
LEVAQUIN SOLUTION;ORAL levofloxacin 021721 2009-07-30
LEVAQUIN TABLET;ORAL levofloxacin 020634

US Patents and Regulatory Information for LEVOFLOXACIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs Inc LEVOFLOXACIN levofloxacin TABLET;ORAL 201484-002 Nov 22, 2013 DISCN No No   Start Trial   Start Trial   Start Trial
Glenmark Generics LEVOFLOXACIN levofloxacin TABLET;ORAL 200250-003 Jun 20, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Celltrion LEVOFLOXACIN levofloxacin TABLET;ORAL 090367-003 Jun 20, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.